BRPI0717930A2 - n-(5-cloro-furan-2-ilcarbonil)-3,7-diazabiciclo [3.3.0]octano, ou sais farmaceuticamente aceitÁveis do mesmo, seu usos, e composiÇço farmacÊutica comprrendendo os mesmos - Google Patents

n-(5-cloro-furan-2-ilcarbonil)-3,7-diazabiciclo [3.3.0]octano, ou sais farmaceuticamente aceitÁveis do mesmo, seu usos, e composiÇço farmacÊutica comprrendendo os mesmos Download PDF

Info

Publication number
BRPI0717930A2
BRPI0717930A2 BRPI0717930-8A BRPI0717930A BRPI0717930A2 BR PI0717930 A2 BRPI0717930 A2 BR PI0717930A2 BR PI0717930 A BRPI0717930 A BR PI0717930A BR PI0717930 A2 BRPI0717930 A2 BR PI0717930A2
Authority
BR
Brazil
Prior art keywords
diazabicyclo
ylcarbonyl
compounds
octane
pharmaceutically acceptable
Prior art date
Application number
BRPI0717930-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Anatoly Mazurov
Lan Miao
Yun-De Xiao
Philip S Hammond
Craig H Miller
Srinivisa Rao Akireddy
V Srinivasa Murthy
Regina C Whitaker
Scott R Breining
Matt S Melvin
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of BRPI0717930A2 publication Critical patent/BRPI0717930A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0717930-8A 2006-11-02 2007-11-01 n-(5-cloro-furan-2-ilcarbonil)-3,7-diazabiciclo [3.3.0]octano, ou sais farmaceuticamente aceitÁveis do mesmo, seu usos, e composiÇço farmacÊutica comprrendendo os mesmos BRPI0717930A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85607906P 2006-11-02 2006-11-02
US60/856,079 2006-11-02
PCT/US2007/083330 WO2008057938A1 (en) 2006-11-02 2007-11-01 Nicotinic acetylcholine receptorsub-type selective amides of diazabicycloalkanes

Publications (1)

Publication Number Publication Date
BRPI0717930A2 true BRPI0717930A2 (pt) 2011-05-10

Family

ID=39233054

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0717930-8A BRPI0717930A2 (pt) 2006-11-02 2007-11-01 n-(5-cloro-furan-2-ilcarbonil)-3,7-diazabiciclo [3.3.0]octano, ou sais farmaceuticamente aceitÁveis do mesmo, seu usos, e composiÇço farmacÊutica comprrendendo os mesmos
BRPI0722387-0A BRPI0722387A2 (pt) 2006-11-02 2007-11-01 Compostos de amidas de diazabicicloalcanos, uso dos mesmos e composição farmacêutica compreendendo os mesmos

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0722387-0A BRPI0722387A2 (pt) 2006-11-02 2007-11-01 Compostos de amidas de diazabicicloalcanos, uso dos mesmos e composição farmacêutica compreendendo os mesmos

Country Status (32)

Country Link
US (6) US8114889B2 (enExample)
EP (2) EP2094703B1 (enExample)
JP (2) JP5539723B2 (enExample)
KR (2) KR20100124356A (enExample)
CN (4) CN102942569B (enExample)
AR (2) AR063451A1 (enExample)
AT (2) ATE509022T1 (enExample)
AU (2) AU2007317433B2 (enExample)
BR (2) BRPI0717930A2 (enExample)
CA (1) CA2663925C (enExample)
CL (1) CL2007003155A1 (enExample)
CO (1) CO6180435A2 (enExample)
CY (1) CY1112374T1 (enExample)
DK (1) DK2094703T3 (enExample)
ES (2) ES2395157T3 (enExample)
HR (1) HRP20110570T1 (enExample)
IL (2) IL197618A (enExample)
MX (1) MX2009004801A (enExample)
MY (2) MY156730A (enExample)
NO (1) NO20091251L (enExample)
NZ (2) NZ587847A (enExample)
PE (2) PE20081441A1 (enExample)
PL (1) PL2094703T3 (enExample)
PT (1) PT2094703E (enExample)
RS (1) RS51834B (enExample)
RU (2) RU2517693C2 (enExample)
SA (1) SA07280584B1 (enExample)
SI (1) SI2094703T1 (enExample)
TW (3) TWI405763B (enExample)
UA (2) UA106718C2 (enExample)
UY (1) UY30686A1 (enExample)
WO (1) WO2008057938A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI405763B (zh) * 2006-11-02 2013-08-21 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
US20110071180A1 (en) * 2008-03-05 2011-03-24 Targacept, Inc. Sub-type selective amides of diazabicycloalkanes
WO2009113950A1 (en) * 2008-03-10 2009-09-17 Astrazeneca Ab Therapeutic combinations of (a) an antipsychotic and (b) an alpha-4/beta-2 (a4b2)-neuronal nicotinic receptor agonist
WO2009147190A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
JP5502076B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド 新規化合物
WO2009147188A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Benzpyrazol derivatives as inhibitors of pi3 kinases
JP2012502039A (ja) * 2008-09-05 2012-01-26 ターガセプト，インコーポレイテッド ジアザビシクロオクタンのアミド及びその用途
WO2010028011A1 (en) * 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclononanes and uses thereof
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
US8524751B2 (en) 2009-03-09 2013-09-03 GlaxoSmithKline Intellecutual Property Development 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
RS53830B1 (sr) 2009-04-30 2015-06-30 Glaxo Group Limited Indazoli supstituisani oksazolom kao inhibitori pi3-kinaze
RU2417082C2 (ru) * 2009-07-14 2011-04-27 Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) Средство для восстановления утраченной памяти в норме и патологии у пациентов всех возрастных групп на основе n, n'-замещенных 3, 7-диазабицикло[3.3.1]нонанов, фармацевтическая композиция на его основе и способ ее применения
JP5536227B2 (ja) 2009-11-18 2014-07-02 スヴェン・ライフ・サイエンシズ・リミテッド α４β２ニコチン性アセチルコリン受容体リガンドとしての二環式化合物
ES2552932T3 (es) 2009-12-29 2015-12-03 Suven Life Sciences Limited Ligandos del receptor nicotínico neuronal de la acetilcolina alfa4beta2
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
AU2014356583B2 (en) 2013-11-26 2019-02-28 F. Hoffmann-La Roche Ag New octahydro-cyclobuta (1,2-c;3,4-c')dipyrrol-2-yl
MA50635A (fr) 2014-03-26 2020-08-12 Hoffmann La Roche Nouveaux composés bicycliques comme inhibiteurs de la production d'autotaxin (atx) et de l'acide lysophosphatidique
CN107106542B (zh) 2014-10-20 2020-05-08 奥伊斯特普安生物制药公司 治疗眼部病状的方法
EP3344619B1 (en) 2015-09-04 2020-10-28 H. Hoffnabb-La Roche Ag Phenoxymethyl derivatives
BR112018006080A2 (pt) 2015-09-24 2018-10-09 F. Hoffmann-La Roche Ag novos compostos bicíclicos como inibidores de dupla ação de atx/ca
WO2017050747A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag New bicyclic compounds as dual atx/ca inhibitors
MA42918A (fr) 2015-09-24 2018-08-01 Hoffmann La Roche Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
AU2016328437A1 (en) 2015-09-24 2018-01-25 F. Hoffmann-La Roche Ag Bicyclic compounds as ATX inhibitors
NZ746468A (en) 2016-04-07 2023-06-30 Oyster Point Pharma Inc Methods of treating ocular conditions
RU2019132254A (ru) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
EP3596060B1 (en) 2017-03-16 2023-09-20 F. Hoffmann-La Roche AG New bicyclic compounds as atx inhibitors
AR111295A1 (es) * 2017-03-20 2019-06-26 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr)
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
MX2022003025A (es) 2019-09-19 2022-04-07 Forma Therapeutics Inc Activacion de la piruvato cinasa r.
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5493026A (en) 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
US5468858A (en) * 1993-10-28 1995-11-21 The Board Of Regents Of Oklahoma State University Physical Sciences N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents
ATE177099T1 (de) * 1993-12-29 1999-03-15 Pfizer Diazabicyclische neurokinin antagonisten
US5457121A (en) 1994-09-02 1995-10-10 Eli Lilly And Company Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5616716A (en) 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
SE9600683D0 (sv) * 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US5726189A (en) 1996-05-03 1998-03-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes
US5952339A (en) 1998-04-02 1999-09-14 Bencherif; Merouane Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release
MXPA02005884A (es) * 1999-12-14 2002-10-23 Neurosearch As Heteroaril-diazabicicloalcanos novedosos.
US6809105B2 (en) * 2000-04-27 2004-10-26 Abbott Laboratories Diazabicyclic central nervous system active agents
WO2002070523A1 (en) 2001-03-07 2002-09-12 Pfizer Products Inc. Modulators of chemokine receptor activity
EP1406900B1 (en) 2001-07-06 2006-10-04 Neurosearch A/S Novel compounds, their preparation and use
SE0202430D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
SE0202465D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
CN1317280C (zh) * 2003-02-27 2007-05-23 神经研究公司 新的二氮杂双环芳基衍生物
JP2006519208A (ja) * 2003-02-27 2006-08-24 ニューロサーチ、アクティーゼルスカブ 新規ジアザビシクロアリール誘導体
US7399765B2 (en) 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
US7365193B2 (en) * 2004-02-04 2008-04-29 Abbott Laboratories Amino-substituted tricyclic derivatives and methods of use
ATE382623T1 (de) * 2004-06-09 2008-01-15 Hoffmann La Roche Octahydropyrrolo(3,4-c)pyrrolderivate und deren verwendung als antivirale mitteln
CA2574307A1 (en) * 2004-07-22 2006-02-02 Cumbre Pharmaceuticals Inc. Rifamycin derivatives for treating microbial infections
CN101193635A (zh) 2005-05-13 2008-06-04 莱西肯医药有限公司 多环化合物及其使用方法
TWI405763B (zh) * 2006-11-02 2013-08-21 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺

Also Published As

Publication number Publication date
MY145602A (en) 2012-03-15
MY156730A (en) 2016-03-15
AR079840A2 (es) 2012-02-22
UA106718C2 (uk) 2014-10-10
PE20110671A1 (es) 2011-10-20
EP2284171A1 (en) 2011-02-16
RS51834B (sr) 2012-02-29
US20100081683A1 (en) 2010-04-01
AU2010219323B2 (en) 2012-05-03
CN101528745A (zh) 2009-09-09
CA2663925A1 (en) 2008-05-15
CN102020646B (zh) 2013-11-13
CN102942569A (zh) 2013-02-27
CN102942569B (zh) 2015-10-28
JP5739398B2 (ja) 2015-06-24
US20130005789A1 (en) 2013-01-03
EP2094703B1 (en) 2011-05-11
CL2007003155A1 (es) 2008-05-16
US20100173932A1 (en) 2010-07-08
CN101528745B (zh) 2011-09-14
RU2009120674A (ru) 2010-12-10
AR063451A1 (es) 2009-01-28
PE20081441A1 (es) 2008-10-30
IL209026A (en) 2014-03-31
TWI405763B (zh) 2013-08-21
JP2013056919A (ja) 2013-03-28
EP2094703A1 (en) 2009-09-02
RU2517693C2 (ru) 2014-05-27
HK1149751A1 (en) 2011-10-14
IL209026A0 (en) 2011-01-31
IL197618A (en) 2013-09-30
PT2094703E (pt) 2011-07-22
US8859609B2 (en) 2014-10-14
AU2007317433B2 (en) 2012-05-10
ES2395212T3 (es) 2013-02-11
DK2094703T3 (da) 2011-08-29
PL2094703T3 (pl) 2011-10-31
CA2663925C (en) 2015-04-21
NO20091251L (no) 2009-05-28
US8114889B2 (en) 2012-02-14
UA98944C2 (ru) 2012-07-10
CN102020646A (zh) 2011-04-20
WO2008057938A1 (en) 2008-05-15
RU2009138600A (ru) 2011-04-27
AU2010219323A1 (en) 2010-09-30
KR20090074051A (ko) 2009-07-03
MX2009004801A (es) 2009-07-31
RU2448969C2 (ru) 2012-04-27
KR101415705B1 (ko) 2014-07-04
ATE509022T1 (de) 2011-05-15
TW201305176A (zh) 2013-02-01
BRPI0722387A2 (pt) 2023-02-23
CY1112374T1 (el) 2015-12-09
TWI454262B (zh) 2014-10-01
EP2284171B1 (en) 2012-02-15
US9580434B2 (en) 2017-02-28
ES2395157T3 (es) 2013-02-08
SA07280584B1 (ar) 2010-11-02
AU2007317433A1 (en) 2008-05-15
US20160039833A1 (en) 2016-02-11
JP5539723B2 (ja) 2014-07-02
TW200826935A (en) 2008-07-01
US8268860B2 (en) 2012-09-18
TWI404532B (zh) 2013-08-11
US8921410B2 (en) 2014-12-30
CN102838605B (zh) 2017-04-26
US20120289572A1 (en) 2012-11-15
HK1133260A1 (en) 2010-03-19
CO6180435A2 (es) 2010-07-19
IL197618A0 (en) 2009-12-24
SI2094703T1 (sl) 2011-07-29
HRP20110570T1 (hr) 2011-09-30
ATE545646T1 (de) 2012-03-15
CN102838605A (zh) 2012-12-26
UY30686A1 (es) 2009-08-03
KR20100124356A (ko) 2010-11-26
NZ587847A (en) 2011-09-30
US20150080576A1 (en) 2015-03-19
TW201114424A (en) 2011-05-01
JP2010509230A (ja) 2010-03-25
NZ575557A (en) 2011-01-28

Similar Documents

Publication Publication Date Title
ES2395212T3 (es) Amidas de diazabicicloalcanos selectivas de subtipo del receptor de acetilcolina nicotínica.
AU2012205208A1 (en) Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes
HK1149751B (en) Amides of diazabicycloalkanes selective for nicotinic acetylcholine receptor sub-types
HK1133260B (en) Nicotinic acetylcholine receptorsub-type selective amides of diazabicycloalkanes

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2538 DE 27-08-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.